SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The quarter ended June 2023 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 7380.20 millions.The Company has registered profit of Rs. 1305.80  millions for the quarter ended June 2023, a growth of 12.93%  over Rs. 1156.30 millions millions achieved in the corresponding quarter of last year.OP of the company witnessed a marginal growth to 1780.50 millions from 1757.20 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 7380.20 7294.60 1.17 7380.20 7294.60 1.17 32163.40 32175.10 -0.04
Other Income 368.00 277.90 32.42 368.00 277.90 32.42 1015.20 762.20 33.19
PBIDT 1780.50 1757.20 1.33 1780.50 1757.20 1.33 9009.30 8320.50 8.28
Interest 2.80 6.80 -58.82 2.80 6.80 -58.82 18.10 19.90 -9.05
PBDT 1950.70 1750.40 11.44 1950.70 1750.40 11.44 8981.50 8416.40 6.71
Depreciation 163.60 158.20 3.41 163.60 158.20 3.41 657.70 681.90 -3.55
PBT 1787.10 1592.20 12.24 1787.10 1592.20 12.24 8323.80 7734.50 7.62
TAX 481.30 435.90 10.42 481.30 435.90 10.42 2276.80 3968.70 -42.63
Deferred Tax -45.00 -34.70 29.68 -45.00 -34.70 29.68 -183.70 -105.00 74.95
PAT 1305.80 1156.30 12.93 1305.80 1156.30 12.93 6047.00 3765.80 60.58
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 24.13 24.09 0.15 24.13 24.09 0.15 28.01 25.86 8.32

Glaxosmithkline Phar Share Price

2451.80 32.70 (1.35%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×